HomeUSAFlagship Pioneering and Samsung Team Up to Advance Groundbreaking Technologies in...

Flagship Pioneering and Samsung Team Up to Advance Groundbreaking Technologies in Translational Science and Medicine

Flagship Pioneering

Flagship Pioneering, a Cambridge, MA-based bioplatform innovation company, and Samsung, announced a collaboration aimed at fostering biopharmaceutical innovation to transform the world of healthcare through advancements in translational science and medicine.

Through this collaboration, Samsung will work alongside Flagship-founded companies, leveraging its technologies and capabilities to accelerate first and best-in-class therapies.

The newly formed strategic partnership is an expansion of the ongoing cooperation between Samsung and Flagship. The collaboration between Samsung and Flagship leverages the expertise of both organizations in the areas of life science technology, artificial intelligence, and CDMO services, and extends across Flagship’s ecosystem of companies.

The collaboration will leverage state-of-the-art technology including artificial intelligence, translational medicine, access to high quality clinical samples and Samsung’s clinical trials infrastructure, and investment by Samsung in Flagship-founded companies.

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, the firm has originated and fostered more than 100 scientific ventures, resulting in more than $70 billion in aggregate value. To date, Flagship has deployed over $3.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current ecosystem comprises 40 companies, including Denali Therapeutics (NASDAQ: DNLI), Foghorn Therapeutics (NASDAQ: FHTX), Generate:Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB) and Tessera Therapeutics.